Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment (2025)

Yao, B., Lei, Z., Gonçalves, M. A. F. V. (2024). Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment. Current cardiology reports, 26(11), 1197-1208. https://doi.org/10.1007/s11886-024-02118-2

Yao, Bing ; Lei, Zhiyong ; Gonçalves, Manuel A.F.V. et al. / Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment. In: Current cardiology reports. 2024 ; Vol. 26, No. 11. pp. 1197-1208.

@article{d865b3f41ae540d7af93902bfca78867,

title = "Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment",

abstract = "Purpose of review: This review aims to evaluate the potential of CRISPR-based gene editing tools, particularly prime editors (PE), in treating genetic cardiac diseases. It seeks to answer how these tools can overcome current therapeutic limitations and explore the synergy between PE and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for personalized medicine. Recent findings: Recent advancements in CRISPR technology, including CRISPR-Cas9, base editors, and PE, have demonstrated precise genome correction capabilities. Notably, PE has shown exceptional precision in correcting genetic mutations. Combining PE with iPSC-CMs has emerged as a robust platform for disease modeling and developing innovative treatments for genetic cardiac diseases. Summary: The review finds that PE, when combined with iPSC-CMs, holds significant promise for treating genetic cardiac diseases by addressing their root causes. This approach could revolutionize personalized medicine, offering more effective and precise treatments. Future research should focus on refining these technologies and their clinical applications.",

keywords = "Cellular reprogramming, CRISPR-based gene editing, Gene therapy, Genetic cardiac diseases, Prime editing",

author = "Bing Yao and Zhiyong Lei and Gon{\c c}alves, {Manuel A.F.V.} and Sluijter, {Joost P.G.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = nov,

doi = "10.1007/s11886-024-02118-2",

language = "English",

volume = "26",

pages = "1197--1208",

journal = "Current cardiology reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "11",

}

Yao, B, Lei, Z, Gonçalves, MAFV 2024, 'Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment', Current cardiology reports, vol. 26, no. 11, pp. 1197-1208. https://doi.org/10.1007/s11886-024-02118-2

Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment. / Yao, Bing; Lei, Zhiyong; Gonçalves, Manuel A.F.V. et al.
In: Current cardiology reports, Vol. 26, No. 11, 11.2024, p. 1197-1208.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment

AU - Yao, Bing

AU - Lei, Zhiyong

AU - Gonçalves, Manuel A.F.V.

AU - Sluijter, Joost P.G.

N1 - Publisher Copyright:© The Author(s) 2024.

PY - 2024/11

Y1 - 2024/11

N2 - Purpose of review: This review aims to evaluate the potential of CRISPR-based gene editing tools, particularly prime editors (PE), in treating genetic cardiac diseases. It seeks to answer how these tools can overcome current therapeutic limitations and explore the synergy between PE and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for personalized medicine. Recent findings: Recent advancements in CRISPR technology, including CRISPR-Cas9, base editors, and PE, have demonstrated precise genome correction capabilities. Notably, PE has shown exceptional precision in correcting genetic mutations. Combining PE with iPSC-CMs has emerged as a robust platform for disease modeling and developing innovative treatments for genetic cardiac diseases. Summary: The review finds that PE, when combined with iPSC-CMs, holds significant promise for treating genetic cardiac diseases by addressing their root causes. This approach could revolutionize personalized medicine, offering more effective and precise treatments. Future research should focus on refining these technologies and their clinical applications.

AB - Purpose of review: This review aims to evaluate the potential of CRISPR-based gene editing tools, particularly prime editors (PE), in treating genetic cardiac diseases. It seeks to answer how these tools can overcome current therapeutic limitations and explore the synergy between PE and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for personalized medicine. Recent findings: Recent advancements in CRISPR technology, including CRISPR-Cas9, base editors, and PE, have demonstrated precise genome correction capabilities. Notably, PE has shown exceptional precision in correcting genetic mutations. Combining PE with iPSC-CMs has emerged as a robust platform for disease modeling and developing innovative treatments for genetic cardiac diseases. Summary: The review finds that PE, when combined with iPSC-CMs, holds significant promise for treating genetic cardiac diseases by addressing their root causes. This approach could revolutionize personalized medicine, offering more effective and precise treatments. Future research should focus on refining these technologies and their clinical applications.

KW - Cellular reprogramming

KW - CRISPR-based gene editing

KW - Gene therapy

KW - Genetic cardiac diseases

KW - Prime editing

UR - http://www.scopus.com/inward/record.url?scp=85203553348&partnerID=8YFLogxK

U2 - 10.1007/s11886-024-02118-2

DO - 10.1007/s11886-024-02118-2

M3 - Article

C2 - 39259489

AN - SCOPUS:85203553348

SN - 1523-3782

VL - 26

SP - 1197

EP - 1208

JO - Current cardiology reports

JF - Current cardiology reports

IS - 11

ER -

Yao B, Lei Z, Gonçalves MAFV, Sluijter JPG. Integrating Prime Editing and Cellular Reprogramming as Novel Strategies for Genetic Cardiac Disease Modeling and Treatment. Current cardiology reports. 2024 Nov;26(11):1197-1208. Epub 2024 Sept 11. doi: 10.1007/s11886-024-02118-2